by Peter Ciszewski | Apr 24, 2018
Thijs Spoor, President of AzurRx, provides an overview of his company’s clinical trial programs, including some key milestones for...
by Peter Ciszewski | Apr 24, 2018
Aspergillus is a group of common moulds found everywhere world-wide, especially in the autumn and winter in the Northern hemisphere. Aspergillus is also common in the home, including bedding. Moulds are also called filamentous fungi.Aspergillosis is an infection...
by Peter Ciszewski | Apr 23, 2018
Other Names: ITP; Autoimmune thrombocytopenic purpura; Thrombocytopenic purpura autoimmune Idiopathic thrombocytopenic purpura (ITP) is a bleeding disorder characterized by too few platelets in the blood. This is because platelets are being destroyed by the immune...
by Peter Ciszewski | Apr 23, 2018
Dr. John Maraganore, CEO of Alnylam Pharmaceuticals discusses how patients have become central to the drug development process....
by Peter Ciszewski | Apr 23, 2018
Catalyst Pharmaceuticals announced the enrollment of the first patient in its new Phase 3 clinical trial of amifampridine phosphate (Firdapse) in patients with muscle-specific kinase (MuSK) antibody positive myasthenia gravis (MuSK-MG). Myasthenia gravis (MG) is a...
